Opus Genetics (NASDAQ: IRD) director trims stake in $2.76 million sale

What happened

Foundation Fighting Blindness Retinal Degeneration Fund sold 556,000 Opus Genetics, Inc. (NASDAQ: IRD) shares on 09/30/2026.

The Form 4 says the shares sold at $4.96 each, for about $2.76 million, and the fund still held 3,236,171 shares afterward.

The filing says the trade was executed in multiple transactions at prices ranging from $4.95 to $5.29.

It also says $4.9568 was the weighted average price, and the report was filed on 10/02/2026.

Key numbers

Metric	Latest	Change	Source
Shares sold	556,000 shares		SEC Form 4
Weighted average price	$4.96		SEC Form 4
Sale value	about $2.76 million		SEC Form 4
Shares held after	3,236,171 shares		SEC Form 4
Sale as share of pre-trade holding	14.7%		Calculated from SEC Form 4

Read more: Opus Genetics (IRD) stock analysis and investment case

Why it matters

OptimistFi's case is that Opus Genetics is a high-risk clinical-stage bet that its inherited-retinal-disease gene-therapy programs can create scarce ophthalmology assets before cash burn and dilution overwhelm common shareholders.

This filing weakens that case because a director cut a large position, and OptimistFi's calculation shows the sale was about 14.7% of the pre-trade holding.

The filing identifies Foundation Fighting Blindness Retinal Degeneration Fund as a director of Opus Genetics, Inc. and says the shares were common stock.

The fund still held 3,236,171 shares after the sale, so the report shows a trim rather than an exit.

That leaves the holder exposed to the same clinical and financing risk that the investment case already centers on, even after the trim.

The sale was split across multiple trades, with prices from $4.95 to $5.29 and a weighted average of $4.9568.

That keeps the read focused on ownership behavior, not on any change in the company's clinical programs or financing outlook.

Browse: stock research on every company OptimistFi covers

What's next

The next quarterly report will show whether the fund keeps reducing the stake or leaves the position unchanged.

Another sale would deepen the negative read-through, while a steady holding would leave this Form 4 as the current baseline for later ownership updates.

The only clear takeaway is that Foundation Fighting Blindness Retinal Degeneration Fund sold shares and remained a holder afterward.

A new sale would make the trim look more deliberate, while no follow-up trade would keep this filing as the benchmark for later ownership updates.

More from OptimistFi